Skip to main content
Figure 1 | BMC Microbiology

Figure 1

From: Potential novel therapeutic strategies in cystic fibrosis: antimicrobial and anti-biofilm activity of natural and designed α-helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia

Figure 1

Time-killing kinetic of AMPs against CF strains. BMAP-27 (■), BMAP-28 (▴), P19(9/B) (×), and Tobramycin () were tested at MIC value against representative P. aeruginosa (Pa6, Pa15, and Pa22), S. maltophilia (Sm138, Sm143, and Sm192), and S. aureus (Sa4, Sa10, and Sa13) CF strains. Controls (♦) were not exposed to drugs. Values are the mean of two independent experiments performed in triplicate. The dotted line indicates a 3-log reduction in viability.

Back to article page

BMC Microbiology

ISSN: 1471-2180

Contact us